Portal de Periódicos da CAPES

Targeting of cancer neoantigens with donor-derived T cell receptor repertoires

2016; American Association for the Advancement of Science; Volume: 352; Issue: 6291 Linguagem: Inglês

10.1126/science.aaf2288

1095-9203

Erlend Strønen, Mireille Toebes, Sander Kelderman, Marit M. van Buuren, Weiwen Yang, Nienke van Rooij, Marco Donia, Maxi-Lu Böschen, Fridtjof Lund‐Johansen, Johanna Olweus, Ton N. Schumacher,

Cancer Immunotherapy and Biomarkers

Outsourcing cancer immunotherapy Successful cancer immunotherapy depends on a patient's T cells recognizing tumor-specific mutations and then waging a lethal attack. Despite tumors harboring many mutations, most individuals have very few T cells that respond to these so-called “neo-antigens.” Strønen et al. isolated T cells from healthy donors that responded to predicted neo-antigens expressed by melanomas taken from three patients, sometimes including neo-antigens that the patient's own T cells ignored (see the Perspective by Yadav and Delamarre). Testing whether such an outsourcing strategy could improve clinical outcomes will be an important next step. Science , this issue p. 1337 ; see also p. 1275